ABL1 and Alzheimer disease: Exclusion of these cases minimally affected the differential protein expression analyses, but increased the discriminative potential in the validation cohorts, which can probably be attributed to the association of several proteins in the panel with AD pathology (e.g., ABL1, THOP1, SMOC2, and ITGB2).